In patients with solid tumours, intracranial injection of anti-HER2 CAR-NK cells in patients with glioblastoma demonstrated that CAR-NK cells are safe and well tolerated when given by this route and can have clinical activity, with stable disease being the best response in this phase 1 trial [69]. Here, ERBB2 is linked to glioblastoma.